🇺🇸 Tociluzumab in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Acute Kidney Injury — 1 report (10%)
2. Alanine Aminotransferase Increased — 1 report (10%)
3. Blood Creatinine Increased — 1 report (10%)
4. Cerebral Disorder — 1 report (10%)
5. Creatinine Renal Clearance Decreased — 1 report (10%)
6. Cytokine Release Syndrome — 1 report (10%)
7. Deep Vein Thrombosis — 1 report (10%)
8. Encephalopathy — 1 report (10%)
9. Fluid Retention — 1 report (10%)
10. Gastrostomy Tube Site Complication — 1 report (10%)

Source database →

Frequently asked questions

Is Tociluzumab approved in United States?

Tociluzumab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tociluzumab in United States?

National Institute of Allergy and Infectious Diseases (NIAID) is the originator. The local marketing authorisation holder may differ — check the official source linked above.